GlassScriptPhysician profile
Tiffany Holmes
NPI 1932562634
$7,900.25
in general payments reported to CMS, 2019-2025
31 companies · $872 in 2025
The $872 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $465 · 2020: $1,798 · 2021: $1,656 · 2022: $1,336 · 2023: $949 · 2024: $824 · 2025: $872.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,645.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,644.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,097.29 | 2019-2024 | Cardiomems |
| Novartis Pharmaceuticals Corporation | $1,131.50 | 2019-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $970.24 | 2019-2025 | Lifevest |
| Medtronic, INC. | $408.08 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $404.68 | 2021-2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $355.16 | 2021-2025 | Eliquis, Camzyos |
| Amgen INC. | $259.69 | 2021-2025 | Repatha, Repatha |
| Pfizer INC. | $253.87 | 2019-2024 | |
| Novo Nordisk INC | $243.94 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $239.02 | 2019-2024 | Farxiga |
| Janssen Pharmaceuticals, INC | $181.87 | 2019-2024 | Xarelto |
| Atricure, INC. | $169.64 | 2022 | |
| Irhythm Technologies, INC. | $166.24 | 2021-2024 | Zio Xt Patch, Zio Monitor |
| Esperion Therapeutics, INC. | $157.38 | 2021-2024 | Nexletol |
| Preventice Services, LLC | $126.79 | 2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $126.27 | 2022-2025 | Verquvo, Capvaxive |
| Bayer Healthcare Pharmaceuticals INC. | $116.51 | 2022 | |
| Heartflow, INC. | $93.17 | 2023-2024 | Ffrct |
| W. L. Gore & Associates, INC. | $81.43 | 2021-2022 | |
| Kiniksa Pharmaceuticals, LTD. | $65.98 | 2023 | Arcalyst |
| Medtronic Vascular, INC. | $56.52 | 2019 | |
| Impulse Dynamics (USA) INC. | $35.43 | 2021-2022 | |
| Alnylam Pharmaceuticals INC. | $24.43 | 2024 | Amvuttra |
| Boston Scientific Corporation | $22.54 | 2023 | |
| Edwards Lifesciences Corporation | $22.00 | 2021 | |
| Cvrx, INC. | $19.05 | 2025 | Barostim Neo System |
| Philips North America LLC | $16.36 | 2022 | |
| Angiodynamics, INC. | $14.83 | 2020 | |
| Astellas Pharma US INC | $14.14 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $13.17 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $13.03 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tiffany Holmes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.